BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 36759438)

  • 21. Fluorescent In Situ Hybridization Must be Preferred to pan-TRK Immunohistochemistry to Diagnose NTRK3-rearranged Gastrointestinal Stromal Tumors (GIST).
    Castillon M; Kammerer-Jacquet SF; Cariou M; Costa S; Conq G; Samaison L; Douet-Guilbert N; Marcorelles P; Doucet L; Uguen A
    Appl Immunohistochem Mol Morphol; 2021 Sep; 29(8):626-634. PubMed ID: 33758144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
    Hung YP; Jo VY; Hornick JL
    Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive 'biomarker piggybacking': an examination of reflexive pan-cancer screening with pan-TRK immunohistochemistry.
    Sholl LM; Zheng M; Nardi V; Hornick JL
    Histopathology; 2021 Aug; 79(2):260-264. PubMed ID: 33682174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
    Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
    Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
    Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
    Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion.
    Xu B; Haroon Al Rasheed MR; Antonescu CR; Alex D; Frosina D; Ghossein R; Jungbluth AA; Katabi N
    Histopathology; 2020 Feb; 76(3):375-382. PubMed ID: 31448442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
    Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
    Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pan-TRK immunohistochemistry as screening tool for NTRK fusions: A diagnostic workflow for the identification of positive patients in clinical practice.
    Vingiani A; Lorenzini D; Conca E; Volpi CC; Trupia DV; Gloghini A; Perrone F; Tamborini E; Dagrada GP; Agnelli L; Capone I; Busico A; Pruneri G
    Cancer Biomark; 2023; 38(3):301-309. PubMed ID: 37545217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. NTRK-rearranged spindle cell neoplasms: a clinicopathological and molecular study of 13 cases with peculiar characteristics at one of the largest institutions in China.
    Yin L; Shi C; He X; Qiu Y; Chen H; Chen M; Zhang Z; Chen Y; Zhou Y; Zhang H
    Pathology; 2023 Apr; 55(3):362-374. PubMed ID: 36641377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NTRK fusions are extremely rare in bone tumours.
    Lam SW; Briaire-de Bruijn IH; van Wezel T; Cleven AHG; Hogendoorn PCW; Cleton-Jansen AM; Bovée JVMG
    Histopathology; 2021 Nov; 79(5):880-885. PubMed ID: 34148257
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of NTRK Fusions in Canadian Solid Tumour Cancer Patients.
    Silvertown JD; Lisle C; Semenuk L; Knapp C; Jaynes J; Berg D; Kaul N; Lachapelle J; Richardson L; Speevak M; Sarras H; Berman DM; Carter R; Feilotter H; Feltis T
    Mol Diagn Ther; 2023 Jan; 27(1):87-103. PubMed ID: 36194351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
    Marchiò C; Scaltriti M; Ladanyi M; Iafrate AJ; Bibeau F; Dietel M; Hechtman JF; Troiani T; López-Rios F; Douillard JY; Andrè F; Reis-Filho JS
    Ann Oncol; 2019 Sep; 30(9):1417-1427. PubMed ID: 31268127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identifying patients with NTRK fusion cancer.
    Solomon JP; Benayed R; Hechtman JF; Ladanyi M
    Ann Oncol; 2019 Nov; 30 Suppl 8():viii16-viii22. PubMed ID: 32223934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of cancers with NTRK gene fusions.
    Gatalica Z; Xiu J; Swensen J; Vranic S
    Mod Pathol; 2019 Jan; 32(1):147-153. PubMed ID: 30171197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma.
    Chiang S; Cotzia P; Hyman DM; Drilon A; Tap WD; Zhang L; Hechtman JF; Frosina D; Jungbluth AA; Murali R; Park KJ; Soslow RA; Oliva E; Iafrate AJ; Benayed R; Ladanyi M; Antonescu CR
    Am J Surg Pathol; 2018 Jun; 42(6):791-798. PubMed ID: 29553955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of
    Koopman B; Kuijpers CCHJ; Groen HJM; Timens W; Schuuring E; Willems SM; van Kempen LC
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of
    Solomon JP; Hechtman JF
    Cancer Res; 2019 Jul; 79(13):3163-3168. PubMed ID: 31196931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
    Elfving H; Broström E; Moens LNJ; Almlöf J; Cerjan D; Lauter G; Nord H; Mattsson JSM; Ullenhag GJ; Strell C; Backman M; La Fleur L; Brunnström H; Botling J; Micke P
    Lung Cancer; 2021 Jan; 151():53-59. PubMed ID: 33310622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.
    Zhang Z; Pang J; Chen L; Chen J; Li J; Liu H; Wang J; Wu H; Liang Z
    Hum Pathol; 2022 Nov; 129():21-31. PubMed ID: 35977594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.